This study is for men with prostate cancer who are experiencing hot flashes due to treatments that lower testosterone (Androgen Deprivation Therapy or ADT). Hot flashes can affect your quality of life, and researchers are looking for better ways to manage them. This study is testing a drug called fezolinetant, which is already approved for hot flashes in menopausal women. The goal is to see if fezolinetant can reduce your hot flashes. The study is looking for 32 men, aged 18 or older, who are currently receiving ADT. Success will be measured by how much your hot flash score is reduced after 28 days.

Study design

This is an interventional study with a planned enrollment of 32 men. Participants will receive fezolinetant at an FDA-approved dose.

What's involved

You would take fezolinetant by mouth once daily for 28 days. Your hot flash score will be measured at the end of this period.

Compensation

Not stated in the trial record.

Follow-up

The primary endpoint is measured at 28 days.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.